Management of bone loss induced by aromatase inhibitors

Cancer Investigation

Volumn 24, Issue 3, 2006, Pages 328-330

  Gnant, Michael ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Aromatase inhibitors; Bisphosphomates; Breast cancer; Cancer treatment induced bone loss

Indexed keywords

AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; TAMOXIFEN;

ADJUVANT THERAPY; BONE DENSITY; BREAST CANCER; CANCER ADJUVANT THERAPY; HUMAN; OSTEOLYSIS; PATIENT MONITORING; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SHORT SURVEY;

AROMATASE INHIBITORS; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; BREAST NEOPLASMS; CLINICAL TRIALS; DIPHOSPHONATES; FEMALE; HUMANS;

EID: 33646468937     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900600633759     Document Type: Short Survey

References (17)

1. ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, alone or in combination) after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005, 365, 60-62.
2. Thuerlimann, B. BIG 1-98 Collaborative Group. Letrozole versus tamoxifen as adjuvant andocrine therapy for postmenopausal women with receptor positive breast cancer. BIG 1-98: a prospective randomized double-blind phase III study. The Breast 2005, 14 (Suppl. 1), S3 (Abst. S4).
3. Jakesz, R.; Jonat, W.; Gnant, M.; et al. Switching of post-menopausal women with endocrine-responsive early breast cancer to anstrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005, 3665, 455-462.
4. Coombes, R.C.; Hall, E.; Gibson, L.J.; et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N. Engl. J. Med. 2004, 350, 1081-1091.
5. Pritchard, K. Aromatase inhibitors in adjuvant therapy of breast cancer: before, instead of, or beyong tamoxifen. J. Clin. Oncol. 2005, 23, 1-3.
6. Goss, P.E.; Ingle, J.N.; Martino, S.; et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N. Engl. J. Med. 2003, 349, 1793-1802.
7. Lønning, P.E.; Geisler, J.; Krag, L.E.; et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J. Clin. Oncol. 2005, 23, 1-12.
8. Hillner, B.; Ingle, J.; Chlebowski, R. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J. Clin. Oncol. 2003, 21, 4042-4057.
9. Brufsky, A.M. Proc. ASCO 2005.
10. Jakesz, R.; Hausmaninger, H.; Kubista, E.; et al. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer - the Austrian Breast ande Colorectal Cancer Study Group Trial 5. J. Clin. Oncol. 2002, 20, 4621-4627.
11. Gnant, M. SABCS 2004.
12. Jordan, V.C.; Fritz, N.F.; Tormey, D.C. Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node-positive patients with breast cancer. Cancer Res. 1987, 47, 624.
13. Shapiro, C.L.; Manola, J.; Leboff, M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J. Clin. Oncol. 2001, 19, 3306.
14. Perez, E. SABCS 2004.
15. Chang, J.T.; Green, L.; Beitz, J. Renal failure with the use of zoledronicacid. N. Engl. J. Med. 2003, 349, 1676-1679.
16. Durie, B.G.M.; Katz, M.; Crowley, J.; et al. N. Engl. J. Med. 2005, 353, 99-102.
17. Lanza, F.L. Gastrointestinal adverse effects of bisphosphonates: etiology, incidence and prevention. Treat. Endocrinol. 2002, 1, 37-43.